Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progressiondoi:10.3389/fonc.2023.1272602HORMONE receptor positive breast cancerCYCLIN-dependent kinase inhibitors...
[2]Miglietta F, Bottosso M, Griguolo G, et al. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022;7(2):100409. [3]Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer:...
they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data
Nancy Lin, MD: It’s a great question because I think we saw the elacestrant data from the San Antonio Breast Cancer Symposium, that was in ER-positive HER2-negative patients. But clearly elacestrant was, at least proof-of-concept wise, a bit better, not dramatically better, but a ...
the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms ...
the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms ...
A research team at Severance Hospital has proposed a new primary treatment strategy for HER2-negative advanced gastric cancer.The oncology team of Yonsei Cancer Center, led by Professor Rha Sun-young, conducted a treatment combining Keytruda with convent
1 In the management of metastatic breast cancer (MBC), treatment options have recently been updated regarding HER2 status. HER2-Low Breast Cancer HER2-low disease is defined as an immunohistochemistry (IHC) score of 1+ or 2+ with a negative in situ hybridization (ISH) result and is seen in...
[3] GianniL, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2 positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superioritytrial with a parallel HER2-negative cohort[J]. Lancet Oncol,2014,15(6):640-647. ...
ByUniversity of Colorado Cancer CenterFEATURINGVirginia Borges April 13, 2023